Prima BioMed’s (IMMP) Sell (E+) Rating Reiterated at Weiss Ratings

Prima BioMed (NASDAQ:IMMP)‘s stock had its “sell (e+)” rating restated by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen lowered shares of Prima BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Prima BioMed presently has a consensus rating of “Hold” and an average price target of $7.00.

Prima BioMed Stock Performance

Shares of Prima BioMed stock opened at $2.02 on Wednesday. Prima BioMed has a 12-month low of $1.32 and a 12-month high of $2.71. The firm’s 50 day simple moving average is $1.72 and its two-hundred day simple moving average is $1.73.

Institutional Trading of Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC grew its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.32% of the company’s stock.

Prima BioMed Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.